Xilio Therapeutics (XLO)
Develops masked immuno-oncology therapies designed to activate within tumors.
$9.04
vs last close+0.00 (+0.05%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 41.93% | 2.76M shares | |
|---|---|---|---|
| 26 holders · as of Jun 30, 2026 | |||
| Insiders | 0.58% | 37.8K shares | |
| 5 holders · as of Mar 30, 2026 | |||
| Strategic holders | 9.89% | 650.4K shares | |
| 1 holder · as of Dec 19, 2024 | |||
| Other | 47.60% | 3.13M shares | |
| remainder | |||
6.58M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (5.78M in the company's Sep 23, 2026 report, 6.58M elsewhere); stakes use the report.
13F, as of Jun 30, 2026
26 holders · 2.76M shares · 11 new positions · 15 increased · 4 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664.0K | 10.10% | 0 | Aug 14, 2026 |
| Orbimed Advisors LLC | 592.3K | 9.01% | +592.3Knew | Aug 14, 2026 |
| Frazier Life Sciences Management, L.P. | 422.5K | 6.43% | 0 | Aug 14, 2026 |
| Stonepine Capital Management, LLC | 226.0K | 3.44% | +161.8K | Aug 17, 2026 |
| Vanguard Capital Management LLC | 178.5K | 2.72% | +54.9K | Aug 13, 2026 |
| Sio Capital Management, LLC | 152.5K | 2.32% | 0 | Aug 14, 2026 |
| Adage Capital Partners GP, L.L.C. | 111.5K | 1.70% | +111.5Knew | Aug 14, 2026 |
| Merck & Co., Inc. | 106.0K | 1.61% | 0 | Aug 7, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 19.90% | 13G | Feb 12, 2026 | |
| GKCC, LLCincl. Yekaterina Chudnovsky | 15.90% | 13G | Sep 27, 2024 | |
| BCLS II Equity Opportunities, LP | 9.99% | 664.0K | 13G | May 15, 2026 |
| Orbimed Advisors LLC | 9.99% | 642.0K | 13G | May 15, 2026 |
| Coastlands Capital LP | 9.99% | 13G | Dec 11, 2025 | |
| Sirenia Capital Management LP | 9.90% | 1.14M | 13G | May 15, 2026 |
| AbbVie Inc. | 9.00% | 13G | Feb 18, 2025 | |
| StemPoint Capital LP | 8.40% | 13G | Feb 17, 2026 | |
| Frazier Life Sciences Public Fund, L.P. | 6.70% | 13G | Feb 13, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 26, 2026 | James Samuel Shannondirector | Purchase | 5,000 | $8.79 | 10,000 |
| Feb 13, 2026 | Gilead Sciences, Inc.10 percent owner | Purchase | 3,739,000 | $0.0001 | 40,384,266 |
| Jan 2, 2026 | Christopher James Frankenfieldofficer: Chief Financial Officer | Sale | 7,030 | $0.6432 | 24,766 |
| Jan 2, 2026 | Kevin M. Brennanofficer: SVP, FINANCE AND ACCOUNTING | Sale | 1,826 | $0.6432 | 6,371 |
House and Senate disclosures
Not reported.